One year in review
One year in review 2020: comorbidities, diagnosis and treatment of primary Sjögren’s syndrome
V. Manfrè1, G. Cafaro2, I. Riccucci3, A. Zabotti4, C. Perricone5, H. Bootsma6, S. De Vita7, E. Bartoloni8
- Clinic of Rheumatology, DAME, University Hospital S. Maria della Misericordia, Udine, Italy.
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
- Clinic of Rheumatology, DAME, University Hospital S. Maria della Misericordia, Udine, Italy.
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
- Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Clinic of Rheumatology, DAME, University Hospital S. Maria della Misericordia, Udine, Italy. salvatore.devita@asuiud.sanita.fvg.it
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
CER13748
2020 Vol.38, N°4 ,Suppl.126
PI 0010, PF 0022
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 32940212 [PubMed]
Received: 29/06/2020
Accepted : 29/07/2020
In Press: 16/09/2020
Published: 22/10/2020
Abstract
Primary Sjögren’s syndrome (pSS) is a complex and heterogeneous disorder characterised by a wide spectrum of glandular and extra-glandular features. The discovery of novel biomarkers allowed to characterise the disease not only phenotypically on the basis of clinical presentation, but also on the basis of the endotype. Moreover, a better stratification of patients has important value in the evaluation of mechanisms underlying the risk of lymphoproliferative disorders in these patients. Finally, novel targeted therapies may open new possibilities for the application of personalised medicine in pSS.
